EPISODE · May 21, 2026 · 11 MIN
AUA26 special: Dr. Bivalacqua discusses the first results of the CORE-008 Cohort CX- Study
from EAU Podcasts · host European Association of Urology
In this episode, UROONCO BCa chief editor Dr. Benjamin Pradere interviews Dr. Trinity Bivalacqua on the first results from CORE-008 Cohort CX- phase 2 study of intravesical cretostimogene grenadenorepvec with gemcitabine in patients with high-risk BCG-exposed or BCG-unresponsive non-muscle invasive bladder cancer. They talk in detail of the rational and results of this cohort, and the role of cretostimogene in treatments of BCG-exposed or BCG-unresponsive bladder cancer. For more details on this study, you can read the abstract on the UROONCO BCa Educational Platform.This interview was recorded at AUA2026. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
Embed this episode
What this episode covers
In this episode, UROONCO BCa chief editor Dr. Benjamin Pradere interviews Dr. Trinity Bivalacqua on the first results from CORE-008 Cohort CX- phase 2 study of intravesical cretostimogene grenadenorepvec with gemcitabine in patients with high-risk BCG-exposed or BCG-unresponsive non-muscle invasive bladder cancer. They talk in detail of the rational and results of this cohort, and the role of cretostimogene in treatments of BCG-exposed or BCG-unresponsive bladder cancer. For more ...
NOW PLAYING
AUA26 special: Dr. Bivalacqua discusses the first results of the CORE-008 Cohort CX- Study
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.